Follow us for updates
© 2020 reportr.world
Read the Story →

FDA Seeks Suspension of AstraZeneca Vaccination for Ages 60 and Below

After reports of blood clots abroad.
by Arianne Merez
Just now
Photo/s: Shutterstock
Shares

The Food and Drug Administration recommended Thursday stopping the inoculation of Filipinos age 60 and below using AstraZeneca's COVID-19 vaccine following reports linking the jab to blood clots.

FDA Director General Eric Domingo said he recommended to the Department of Health the suspension of the use of the AstraZeneca vaccine for the said age group.

"We asked DOH na kung mayroon pa pong mga natitirang AstraZeneca vaccines siguro ay huwag muna natin gamitin sa mga people age 60 and below until we get clearer evidence and guidance from the WHO at sa ating mga experts," Domingo said in a televised briefing.

Domingo however clarified that the Philippines has not reported any case of blood clotting from the use of AstraZeneca jabs.

ALSO READ:

Clots are AstraZeneca Vaccine's Latest Issue

'Don't Panic': WHO Says on AstraZeneca Vaccines

The European Medicines Agency (EMA) had recommended that a dangerous type of blood clot should be listed as a "very rare side effect" of the AstraZeneca jab.

Continue reading below ↓

Questions on whether there are links between the jabs and the highly unusual blood clots among those getting them have been raised in recent weeks particularly in Europe.

The EMA however has been reluctant to draw a straight cause-and-effect line between the vaccine and the rare blood clots. The risk of death, based on data as of March 22, is one in 1.4 million.

Supplies of AstraZeneca vaccines already ran out in the Philippines and additional jabs are expected to come in the next month. This, according to Domingo, would provide local health experts enough time to review guidelines for its use.

"Ang susunod na ine-expect ay within one month pa. So, that will give us time to study the evidence and to see kung magkakaroon tayo ng panibagong guidance," Domingo said.

-with a report from Agence France-Presse

Latest Headlines
Read Next
Recent News
The news. So what? Subscribe to the newsletter that explains what the news means for you.
The email address you entered is invalid.
Thank you for signing up to On Three, reportr's weekly newsletter delivered to your mailbox three times a week. Only the latest, most useful and most insightful reads.
By signing up to reportr.world newsletter, you agree to our Terms of Service and Privacy Policy.